Scarica l'app Stockscreener
15.85
9.06%
-1.58
Precedente Chiudi:
$17.43
Aprire:
$17.44
Volume 24 ore:
21,590
Relative Volume:
0.13
Capitalizzazione di mercato:
$142.14M
Reddito:
-
Utile/perdita netta:
$-29.28M
Rapporto P/E:
-1.1673
EPS:
-13.5784
Flusso di cassa netto:
$-27.36M
1 W Prestazione:
-6.76%
1M Prestazione:
-20.19%
6M Prestazione:
+58.90%
1 anno Prestazione:
-4.37%
Intervallo 1D:
$15.85
$18.00
Intervallo di 1 settimana:
$15.85
$19.00
Portata 52W:
$6.27
$39.75
Promis Neurosciences Inc Stock (PMN) Company Profile
Nome
Promis Neurosciences Inc
Settore
Industria
Telefono
416-847-6898
Indirizzo
SUITE 200, 1920 YONGE STREET, TORONTO
Compare PMN vs VRTX, REGN, ALNY, ARGX, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMN
Promis Neurosciences Inc
|
15.85 | 156.31M | 0 | -29.28M | -27.36M | -13.58 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Promis Neurosciences Inc Borsa (PMN) Ultime notizie
ProMIS Neurosciences 2025 Annual Report: Pipeline, Risks, and Strategic Objectives for Alzheimer’s Drug Development - Minichart
ProMIS Neurosciences (PMN) files $50M at-the-market sales supplement - Stock Titan
ProMIS Neurosciences 10-K: $0 Revenue, ($22.61) EPS, Net Loss $39.72M - TradingView
Alzheimer’s antibody lead and ALS programs at ProMIS (NASDAQ: PMN) - Stock Titan
ProMIS Neurosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - marketscreener.com
ProMIS Neurosciences reports $39.7M net loss for FY2025, cash $6.1M; raises $75.5M in Feb 2026 - TradingView
Heavy 2025 loss but big AD bet for ProMIS Neurosciences (PMN) with $175M funding - Stock Titan
Alzheimer's drug trial enrolls 144 patients with no serious side effects - Stock Titan
Promis Neurosciences (PMN) to Release Earnings on Monday - Defense World
How does ProMIS Neurosciences Inc perform in inflationary periods2026 Technicals & Reliable Price Breakout Alerts - baoquankhu1.vn
If You Invested $1,000 in Promis Neuroscie (PMN) - Stock Titan
Activity Recap: How cyclical is ProMIS Neurosciences Incs revenue streamDollar Strength & Free Daily Entry Point Trade Alerts - baoquankhu1.vn
ProMIS Neurosciences (PMN) registers 13.83M shares after $75.5M private placement - Stock Titan
Wellington holds 9.99% of ProMIS Neurosciences (NASDAQ: PMN) via shares and warrants - Stock Titan
ProMIS Neurosciences to Present Data on ALS & Parkinsons Disease Programs at Alzheimer’s Disease/Parkinson’s Disease 2026 International Conference (AD/PD™) - Toronto Star
ProMIS Neurosciences, Inc. (PMN) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Abg V Siv X Ltd Net Worth (2026) - GuruFocus
Abg V Siv Ix Ltd Net Worth (2026) - GuruFocus
Sentiment Recap: Can ProMIS Neurosciences Inc. continue delivering strong returns2026 Earnings Impact & Weekly Chart Analysis and Guides - baoquankhu1.vn
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Promis Neurosciences (NASDAQ:PMN) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World
Published on: 2026-03-10 05:13:34 - baoquankhu1.vn
PMN Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Trade Report: Can ProMIS Neurosciences Inc continue delivering strong returnsJuly 2025 Fed Impact & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc with Recent Share Purchase - GuruFocus
ProMIS Neurosciences (PMN) director purchases 2,000 common shares in open market - Stock Titan
Published on: 2026-03-05 21:52:27 - baoquankhu1.vn
Eugene Williams Increases Stake in ProMIS Neurosciences Inc - GuruFocus
Promis Neurosciences (NASDAQ:PMN) Director Eugene Williams Buys 2,000 Shares - MarketBeat
Eugene Williams Acquires 1,000 Shares of Promis Neurosciences (NASDAQ:PMN) Stock - MarketBeat
ProMIS Neurosciences, Inc. (PMN.TO) Competitors - Meyka
PMN Stock Price and Chart — NASDAQ:PMN - TradingView
ProMIS Neurosciences : PMN - 24/7 Wall St.
Ally Bridge entities disclose ProMIS (PMN) shares and warrant terms - Stock Titan
PMN PE Ratio & Valuation, Is PMN Overvalued - Intellectia AI
Can ADMA Biologics Inc deliver consistent EPS growthJuly 2025 Breakouts & Short-Term Trading Alerts - baoquankhu1.vn
Insider Buying: Johanne Kaplan Acquires Shares of ProMIS Neurosc - GuruFocus
Insider buy: ProMIS Neurosciences (PMN) CDO acquires 1,629 shares at $15.35 - Stock Titan
Final Results - ADVFN
What to expect from Gossamer Bio’s late-stage lung disease study - statnews.com
ProMIS Neurosciences CEO touts “watershed year” as PMN310 Alzheimer’s Phase 1b data nears - Defense World
Is ProMIS Neurosciences Inc. stock positioned well for digital economyWeekly Trend Recap & Smart Swing Trading Techniques - mfd.ru
Promis Neurosciences (NASDAQ:PMN) Cut to “Strong Sell” at Wall Street Zen - Defense World
PMN Should I Buy - Intellectia AI
SPHERA FUNDS MANAGEMENT LTD. Acquires Additional Shares in ProMIS Neurosciences Inc. - GuruFocus
ProMIS Neurosciences: Phase 1b Alzheimer's trial fully enrolled and financed, with pivotal data expected in 2026 - TradingView
Is ProMIS Neurosciences Inc. (23J0) stock a safe buy pre earningsJobs Report & Weekly Breakout Stock Alerts - mfd.ru
Guggenheim Remains a Buy on ProMIS Neurosciences (PMN) - The Globe and Mail
Insider Stock Purchases: February 06, 2026 - Quiver Quantitative
ProMIS Neurosciences (PMN) Rating Maintained but Price Target Sl - GuruFocus
ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 - The Manila Times
Promis Neurosciences Inc Azioni (PMN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):